DIRECTORS' REPORT

The Directors are pleased to present the accounts of the company for the quarter ended March 31, 2014.

Business Review

Work on renovation of our plant was completed in January 2014. Approval letter for the plant from Drugs Regulatory Authority of Pakistan was received on March 21, 2014 after which our factory started production from March 24, 2014. There are some teething problems with the newly installed machines. However, these will be overcome in a few days after which normal production should commence.

Because of closure of our major production line due to renovation, our sales have been badly impacted. Also because of delay in completion of the renovation project, our stock which had been built for this period has been fully exhausted. As a result, our sales for the quarter were only Rs.215.5 million compared with Rs.259.3 million achieved last year showing a decline of 17%. For the nine months, our sales at Rs.758.1 million were 18% lower compared with the same period last year.

The reduction in sales coupled with increase in input costs had a devastating effect on our profit. Also because of reduced production volumes and abnormal increase in cost of utilities, our cost of production is much higher than our selling prices. As a result, we are incurring gross loss on all goods produced and sold during this period. According to International Accounting Standards, stocks are required to be valued at the lower of cost or net realizable value. Since our cost of finished goods as at March 31, 2014 was much higher than the net realizable value, we had to bring it down to net realizable value because of which other operating expenses have increased to Rs.56.2 million compared with Rs.15.0 million incurred last year. Because of the above for the nine months ending March 31, 2014 we incurred a loss before taxation of Rs.199.9 million compared with profit before taxation of Rs.32.1 million earned last year.

Future Outlook

With the start of production of plabottle, we hope to see some improvement in the sales and profit in the coming months. However, the goods being produced currently can't be sold till the approval of stability data by the Drugs Regulatory Authority of Pakistan. We hope that this step will also be completed soon so that we can start normal sale of our products. However, till such time, sales and profits of your company will continue to remain under tremendous pressure.

Also much depends on the Pricing Policy of the Government. Till the time a Pricing Policy is announced by the government which is transparent and fair to both the consumers and the companies, our profits will continue to remain under pressure. It is pertinent to note that prices of infusion solutions in Pakistan are among the lowest in the world including India because of which it is very difficult for your company to make reasonable profits and make further investments.

On behalf of the Board

Abid Hussain
Chief Executive Officer

Karachi

Dated: April 22, 2014



Quarterly Accounts for the quarter ended March 31, 2014

OTSUKA PAKISTAN LIMITED CONDENSED INTERIM BALANCE SHEET AS AT MARCH 31, 2014

CONDENSED INTERIM BALANCE SHEET AS AT MARCH 31, 2014 ASSETS		(Un-Audited) March 31, 2014 Rupees	Restated (Audited) June 30, 2013 in '000
Non-current assets Property, plant and equipment Long-term loans - considered good Long-term deposits Deferred tax asset - net	4	733,477 4,965 783 35,068 774,293	447,570 5,574 743
Current assets Stores and spares Stock-in-trade Trade debts - unsecured Loans and advances - considered good Trade deposits, short-term prepayments and other receivables Taxation Cash and bank balances		47,803 469,898 117,590 34,196 29,648 79,422 8,410 786,967	44,998 502,998 125,007 44,734 21,786 30,712 2,654 772,889
Total assets EQUITY AND LIABILITIES		1,561,260	1,226,776
EQUITY Authorised capital 20,000,000 (June 30, 2013: 10,000,000) ordinary shares of Rs 10 each Issued, subscribed and paid up capital 11,000,000 (June 30, 2013: 10,000,000) ordinary shares of Rs 10 each Revenue reserves Shareholders' equity		200,000 110,000 210,980 320,980	100,000 100,000 387,907 487,907
LIABILITIES			
Non-current liabilities Long-term finance Deferred tax liability - net	5	270,833	100,000 6,536
Current liabilities Trade and other payables Current maturity of long-term finance Short-term running finance - secured Mark-up accrued	5	292,669 54,167 598,762 23,849 969,447	251,881 - 365,344 15,108 632,333
Total equity and liabilities		1,561,260	1,226,776
CONTINGENCIES AND COMMITMENTS	6		

The annexed notes 1 to 12 form an integral part of this condensed interim financial information.

Karachi K

Chief Executive

OTSUKA PAKISTAN LIMITED CONDENSED INTERIM PROFIT AND LOSS ACCOUNT(UN-AUDITED) FOR THE NINE MONTHS AND QUARTER ENDED MARCH 31, 2014

	Nine months ended March 31,		Quarter e March		
-	2014	2013	2014	2013	
	***************************************	Rupees in	1 '000		
Net sales	758,052	926,379	215,528	259,295	
Cost of sales	(737,541)	(667,999)	(214,899)	(187,645)	
Gross profit	20,511	258,380	629	71,650	
Selling and distribution expenses	(113,450)	(135,137)	(38,732)	(42,273)	
Administrative and general expenses	(48,650)	(49,591)	(16,026)	(18,757)	
-	(141,589)	73,652	(54,129)	10,620	
Other income	36,096	11,355	2,235	3,525	
-	(105,493)	85,007	(51,894)	14,145	
Other operating expenses	(56,158)	(14,962)	(4,057)	(3,616)	
Operating (loss) / profit	(161,651)	70,045	(55,951)	10,529	
Financial charges	(38,291)	(37,969)	(17,970)	(13,269)	
(Loss) / profit for the period before taxation	(199,942)	32,076	(73,921)	(2,740)	
Taxation - net	32,802	(12,487)	(2,157)	699	
(Loss) / profit for the period after taxation	(167,140)	19,589	(76,078)	(2,041)	
,			-		
		Rupe	es		
(Loss) / earnings per share - basic and diluted	(15.19)	1.78	(6.92)	(0.19)	

The annexed notes 1 to 12 form an integral part of this condensed interim financial information.

Chief Executive

OTSUKA PAKISTAN LIMITED CONDENSED INTERIM STATEMENT OF COMPREHENSIVE INCOME (UN-AUDITED) FOR THE NINE MONTHS AND QUARTER ENDED MARCH 31, 2014

	Nine months ended March 31,		Quarter ended March 31,	
	2014	2013	2014	2013
		ı '000	***************************************	
(Loss) / profit for the year after taxation	(167,140)	19,589	(76,078)	(2,041)
Items that will not be reclassified to profit or loss				
Remeasurement of post retirement benefit				
obligations - net of tax	213	916	107	458
Total comprehensive (loss) / income for the period	(166,927)	20,505	(75,971)	(1,583)

The annexed notes 1 to 12 form an integral part of this condensed interim financial information.

Chief Executive

3

OTSUKA PAKISTAN LIMITED CONDENSED INTERIM CASH FLOW STATEMENT (UNAUDITED) FOR THE NINE MONTHS ENDED MARCH 31, 2014

N.	Nine month ote March	
	2014	2013
	Rupees	
CASH FLOWS FROM OPERATING ACTIVITIES		
(Loss) / Profit for the period before taxation	(199,942)	32,076
Adjustment for non-cash and other items		
Depreciation	46,281	49,638
Gain on disposal of property, plant and equipment	(158)	(2,827
Provision for slow moving and obsolete stock-in-trade	16,742	1,295
Provision for stents	1,619	2,060
Provision for impairment of trade debts	318	271
Mark-up expense	38,291	37,544
	103,093	87,981
Operating (deficit) / surplus before working capital changes	(96,849)	120,057
Movement in working capital		
(Increase) / decrease in current assets		
Stores and spares	(2,805)	(2,220
Stock-in-trade	14,739	(102,235
Trade debts - unsecured	7,099	40,985
Loans and advances	10,538	(14,169
Trade deposits, short-term prepayments and other receivables	(7,862)	(1,978
(Pearsons) (Ingreson In comment Habilitation	21,709	(79,617
(Decrease) / Increase in current liabilities Trade and other payables	41,001	(36,653
Interest paid	(48,531)	(30,330
Taxes paid	(57,512)	(19,651
Decrease / (increase) in long-term deposits	(40)	A11151
Decrease / (increase) in long-term loans	609	278
	(105,474)	(49,703
Net cash used in operating activities	(139,613)	(45,916
CASH FLOWS FROM INVESTING ACTIVITIES		
Fixed capital expenditure	(313,559)	(162,674
Proceeds from disposal of property, plant and equipment	510	4,497
Net cash used in investing activities	(313,049)	(158,177
CASH FLOWS FROM FINANCING ACTIVITIES		
Long-term finance obtained	225,000	100,000
Dividends paid	-	(9,943
Net cash inflow from / (outflow on) financing activities	225,000	90,057
Net decrease in cash and cash equivalents	(227,662)	(114,038
Cash and cash equivalents at the beginning of the period	(362,690)	(312,785
Cash and cash equivalents at the end of the period	8 (590,352)	(426,82

The annexed notes 1 to 12 form an integral part of this condensed interim financial information.

Chief Executive

10

Karachi)

OTSUKA PAKISTAN LIMITED CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY (UN-AUDITED) FOR THE NINE MONTHS ENDED MARCH 31, 2014

	Issued,	ued, Revenue rese		es	
	subscribed and paid-up capital	General reserve	Unappro- priated profit Rupees in '00	Sub total	Total
			tupees iii oo	U	
Balance as at July 1, 2012 as previously reported	100,000	297,500	107,574	405,074	505,074
Effect of change in accounting policy due to application of IAS 19 (Revised) - net of tax (note 3.1.1)	(4):	-	(6,032)	(6,032)	(6,032)
Balance as at July 1, 2012 - restated	100,000	297,500	101,542	399,042	499,042
Interim dividend for the year ending June 30, 2013 at Re 1.00 per share declared on October 17, 2012	-	84	(10,000)	(10,000)	(10,000)
Transfer to general reserve	2	80,000	(80,000)	-	2
Total comprehensive income for the period ended March 31, 2013		-	20,505	20,505	20,505
Balance as at March 31, 2013 - restated	100,000	377,500	32,047	409,547	509,547
Balance as at July 1, 2013 as previously reported	100,000	377,500	14,445	391,945	491,945
Effect of change in accounting policy due to application of IAS 19 (Revised) - net of tax (note 3.1.1)		=	(4,038)	(4,038)	(4,038)
Balance as at July 1, 2013 - restated	100,000	377,500	10,407	387,907	487,907
Issuance of bonus shares	10,000	(10,000)	•	(10,000)	Ŧ
Total comprehensive loss for the period ended March 31, 2014	(2)	÷	(166,927)	(166,927)	(166,927)
Balance as at March 31, 2014	110,000	367,500	(156,520)	210,980	320,980

The annexed notes 1 to 12 form an integral part of this condensed interim financial information.

Chief Executive

irecto

OTSUKA PAKISTAN LIMITED NOTES TO AND FORMING PART OF THE CONDENSED INTERIM FINANCIAL INFORMATION (UNAUDITED) FOR THE NINE MONTHS ENDED MARCH 31, 2014

1 LEGAL STATUS AND NATURE OF BUSINESS

The Company is incorporated in Pakistan as a public limited company and is listed on the Karachi and Lahore Stock Exchanges. The address of its registered office is 30-B, S.M.C.H. Society, Karachi, Pakistan. It is engaged in the manufacturing, marketing and distribution of intravenous infusions and trading in pharmaceutical products, nutritional foods and medical equipment. The Company is an indirect subsidiary of Otsuka Pharmaceutical Company Limited, Japan.

2 BASIS OF PREPARATION

2.1 Statement of compliance

This condensed interim financial information has been prepared in accordance with approved accounting standards as applicable in Pakistan for interim financial reporting. Approved accounting standards comprise of such International Financial Reporting Standards (IFRSs) issued by the International Accounting Standards Board as are notified under the Companies Ordinance, 1984, and the directives issued by the Securities and Exchange Commission of Pakistan (SECP). Wherever the requirements of the Companies Ordinance, 1984, or the directives issued by the SECP differ with the requirements of IFRSs, the requirements of the Companies Ordinance, 1984 or the directives issued by the SECP prevail.

The disclosures made in this condensed interim financial information have, however, been limited based on the requirements of International Accounting Standard 34: 'Interim Financial Reporting'. This condensed interim financial information does not include all the information and disclosures required in a full set of financial statements and should be read in conjunction with the annual published audited financial statements of the Company for the year ended June 30, 2013.

3 ACCOUNTING POLICIES

3.1 The accounting policies and methods of computation of balances adopted in the preparation of this condensed interim financial information are the same as those applied in the preparation of the annual published financial statements of the Company for the year ended June 30, 2013, except for the change as described in note 3.1.1 below.

3.1.1 Change in accounting policy

Consequent to the revision of IAS 19 "Employee Benefits" which is effective for annual periods beginning on or after January 1, 2013, the Company has changed its accounting policy wherein, the actuarial gains and losses (remeasurement gains/losses) on employees' retirement benefit plans are recognised immediately in Comprehensive Income and past service costs are recognised in the Profit and Loss Account as they are incurred. Previously, the actuarial gains/losses in excess of the corridor limit were recognised in the Profit and Loss Account over the remaining service life of the employees whereas past service cost was recognised in the Profit and Loss Account on a straight line basis over the average period until the benefits become vested. The change in accounting policy has been accounted for retrospectively in accordance with the requirements of IAS 8, 'Accounting Policies, Changes in Accounting Estimates and Errors' and corresponding figures have been restated as follows.

	(Unaudited)	(Audited)	(Audited)
	March 31,	June 30,	June 30,
	2014	2013	2012
	***************************************	Rupees in '000	
Impact on Condensed Interim Balance Sheet /			
Balance Sheet as at June 30, 2013			
Increase in other liabilities	5,795	6,118	9,139
Decrease in deferred tax liability	(1,970)	(2,080)	(3,107)
(Increase) / decrease in revenue reserves	3,825	4,038	6,032





	(Unaudited) March 31, 2014	(Unaudited) March 31, 2013*	(Audited) June 30, 2013	(Audited) June 30, 2012
	100 100 March 10	Rupees	in '000	
Impact on Condensed Interim Profit and Loss Account / Profit and loss account for the year ended June 30, 2013				
Decrease in administrative and general expenses	2	123	246	47
Effect of related taxation	*	(42)	(84)	
Increase in profit after taxation	Ē	81	162	
Impact on Condensed Interim Statement of Comprehensive Income / Statement of Comprehensiv Income for the year ended June 30, 2013	re			
Remeasurements of post employment obligations	213	916	1,832	2
Impact on Condensed Interim Statement of Changes in Equity / Statement of Changes in Equity for the year ended June 30, 2013 Increase / (decrease) in unappropriated profit				
- Cumulative effect - prior years	- (4,038)	(6,032)	(6,032)	(6,032)
- Gain / (charge) for the current period	213	997	1,994	
	(Unaudited) March 31, 2014	(Unaudited) March 31, 2013 *	(Audited) June 30, 2013	(Audited) June 30, 2012
		Rup	ees	
Increase/ (decrease) in earning per share - basic and diluted	5	0.01	0.01	(±),

There is no impact of this change on the cash flow statement for the current or prior periods.

3.2 There are certain other new and amended standards and interpretations that are mandatory for the Company's accounting periods beginning on or after July 1, 2013 but are considered not to be relevant or do not have any material effect on the Company's operations and are, therefore, not detailed in this condensed interim financial information.

		Note	(Unaudited) March 31, 2014	(Audited) June 30, 2013	
4	PROPERTY, PLANT AND EQUIPMENT		Rupees	in '000	
	Operating fixed assets	4.1	209,286	246,343	
	Capital work-in-progress	4.2	524,191	201,227	
			733,477	447,570	
			733,477	_	447,570

4.1 The following additions to and disposals of operating fixed assets have been made during the period:

		Nine months ended March 31, 2014				
	Building on leasehold land	Plant and machinery	Furniture, fixtures and equipment	Vehicles	Fork lifter	Total
			Rupees	in '000		
Additions	3,833	3,806	940	997	*	9,576
Disposals:						
Cost	-	*	217	840	-	1,057
Accumulated depreciation		-	(217)	(489)		(706)
	**	=1		351	= (0)	351



^{*}Determined on a proportionate basis

	Building on leasehold land	Plant and machinery	Furniture, fixtures and equipment	Vehicles	Fork lifter	Total
			Rupees i	n '000		
Additions	464	34,706	2,376	6,870	2	44,416
Disposals:						
Cost		20	1,122	5,398	-	6,540
Accumulated depreciation	9	(17)	(1,122)	(3,731)	~	(4,870)
	*	3	-	1,667	8	1,670
					(Unaudited)	(Audited)

		Note	(Unaudited) March 31, 2014	(Audited) June 30, 2013
1.2	Capital work-in-progress		Rupees	in '000
	Stores and spares held for capital expenditure		8,053	8,316
	Expenditure incurred in relation to Balancing, Modernisation and Replacement (BMR) Project		428,502	53,827
	Plant and machinery for BMR Project in transit		-	136,132
	Others		87,636	2,952
			524,191	201,227
5	LONG TERM FINANCE - SECURED			
	From banking company			
	Total facility utilised under mark-up arrangements	5.1	325,000	100,000
	Less: Current maturity		(54,167)	-
			270,833	100,000
	· · · · · · · · · · · · · · · · · · ·			

As at March 31, 2014, the Company has fully utilised the term finance facility available from the Bank of Tokyo-Mitsubishi UFJ, Limited amounting to Rs 325 million. This loan is being used to finance the BMR project which is currently in progress. The loan is repayable in semi-annual instalments by January 2017. It carries markup at the rate of 6 months KIBOR + 1.75% per annum on the outstanding balance of the facility. The facility is secured by first paripassu hypothecation and / or first equitable mortgage charge on all of the Company's present and future fixed asset including but not limited to land, buildings, plant and machinery, equipment, furniture and fixtures, etc.

6 CONTINGENCIES AND COMMITMENTS

5

6.1 On August 2009, a notice of demand was served on the Company by the Deputy Commissioner of Income Tax (DCIT) for an amount of Rs 5.721 million (June 30, 2013: Rs 5.721 million) including additional tax amounting to Rs 0.457 million (June 30, 2013: Rs 0.457 million) under sections 161, 162 and 205 of the Income Tax Ordinance, 2001 out of which the Company has already paid an amount of Rs 1.50 million (June 30, 2013: Rs 1.50 million). The Company has filed an appeal against the order of the DCIT which is pending adjudication. As on December 31, 2013, no provision has been made in this condensed interim financial information in respect of the amount of Rs 5.721 million (June 30, 2013: Rs 5.721 million) as the management is confident that the matter will be decided in favour of the Company.

On December 30, 2013, a notice under section 122(9) of-the Income Tax Ordinance, 2001 was served by the Additional Commissioner Inland Revenue (ACIR) which required the Company to furnish explanations in respect of certain issues that were identified in the tax return of tax year 2012 filed with the Federal Board of Revenue (FBR). The Company has submitted the desired explanations through their tax advisors for which a response is awaited.

		(Unaudited) March	(Audited) June
		31, 2014	30, 2013
6.2	Commitments represent:	Rupees	in '000
	Capital expenditure contracted for but not incurred	29,116	73,708
	Letters of credit	57,499	201,269
	Letters of guarantee	9,287	9,287

There were no other contingencies and commitments outstanding as on March 31, 2014 and June 30, 2013.



7 TRANSACTIONS WITH RELATED PARTIES

	(Unaudited) Nine months ended March 31, 2014				(Unaudited)	
u .	Parent company	Other associated undertakings	Key management personnel	Other related parties	Total	Nine months ended March 31, 2013
Transactions during the period			Rupe	es in '000		
Net sales net of discounts allowed Rs 69.850						
million (2013: Rs 83.776 million)		407,469			407.400	405.254
Other sales discounts / claims		407,405			407,469	486,251 700
Inventory purchased	33,796	103,957			137,753	
Advance to Efroze Chemicals Industries (Private)	23,720	103,557			157,755	66,263
Limited	20	2			-	4 700
Consultancy fees			1,800		1.800	4,799
Salaries and benefits to key management		70	1,000	-	1,800	1,900
personnel			50,243		50.242	45 307
Contribution to Employees' Provident Fund	13		2,597		50,243	46,287
Contribution to Employees' Gratuity Fund		27			2,597	2,353
and the state of t			1,803	5	1,803	1,563
	(Unaudited)					
	As at March 31, 2014				000000000000000000000000000000000000000	
	Parent company	Other associated undertakings	Key management personnel	Other related parties	Total	(Audited) June 30, 2013
	Rupees in '000					
Balance outstanding as at the end of the period / year						
Receivable from Hospital Supply Corporation						
against sale of goods		84,893	· ·	41	84,893	95.119
Advance to Efroze Chemicals Industries (Private)					01,033	33,113
Limited	1415	11,198	8	14:	11,198	11,198
Trade and other payables						
Payable to Otsuka Pharmaceutical Company						
Limited, Japan	33,796	543			22 705	
Payable to PT Otsuka, Indonesia	33,790	5,035	-		33,796	5
Payable to Microport Medical, Shanghai	8				5,035	-
Payable to Otsuka Pharmaceutical		27,947	-	-	27,947	27,570
Factory Incorporation		2 522			2.525	-
Payable to Thai Otsuka Pharmaceutical		2,522		(*)	2,522	1,824
Company Limited, Thailand		25 142			22.70	22 000
Payable to Employees' Provident Fund		25,143	=	* **	25,143	18,473
Payable to Employees' Frovident Fund	**	-	-	2,514	2,514	2,157
ayable to chiployees Gratuity rund	0	1.7		8,408	8,408	2,546

The Company enters into transactions with related parties for the sale of its products, purchase of raw materials, finished goods and spare parts, toll manufacturing arrangements and for rendering of certain services. Sales to related parties represent sales made to Hospital Supply Corporation which is the sole distributor of the Company's products in the southern region. The Company allows discount to the distributor on trade price based on agreed terms. In addition to the discount given at the time of sale, the Company also offers specific discounts based on product promotion policies. Purchases from related parties primarily represent purchases of raw materials and finished goods from Otsuka group companies.

Remuneration to key management personnel is based on the agreed terms of employment with such personnel.

Contributions to and accruals in respect of staff retirement benefit plans are made in accordance with actuarial recommendations and terms of contribution plans.

8 CASH AND CASH EQUIVALENTS

Cash and bank balances

Short-term running finance utilised under mark-up arrangements

Cash and cash equivalents included in the cash flow statement comprise the following items included in the condensed interim balance sheet:

(Unaudited)	(Unaudited)			
March 31,	March 31,			
2014	2013			
Rupees	in '000			
8,410	2,893			
(598,762)	(429,714)			
(590,352)	(426,821)			



9 SEGMENT INFORMATION

9.1 This condensed interim financial information has been prepared on the basis of a single reportable segment.

Sales from Intravenous Solutions represent 77.26 percent while sales from others represent 22.74 percent (March 31, 2013; 83.42 percent and 16.58 percent) respectively of the total sales of the Company. Sales have been geographically restricted to Pakistan during the current and the prior period.

Sales to Hospital Supply Corporation (a related party of the Company) which is the sole distributor in the southern region was around 53.75 percent during the period ended March 31, 2014 (March 31, 2013: 52.5 percent).

9.2 All non-current assets of the Company as at March 31, 2014 are located in Pakistan.

10 CORRESPONDING FIGURES

Corresponding figures have been rearranged and reclassified wherever necessary for the purpose of comparison and better presentation. There were no major reclassifications in this condensed interim financial information during the current period.

11 DATE OF AUTHORISATION FOR ISSUE

This condensed interim financial information was authorised for issue on April 22, 2014 by the Board of Directors of the Company.

12 GENERAL

Chief Executive

Figures in this condensed interim financial information have been rounded off to the nearest thousand rupees.